A new Phase 2 pilot study shows that giving spores of a non-toxic C. difficile bacteria by mouth is effective in stopping repeated bouts of C. diff infection, a major complication of hospitalization.

An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile. | Drug Discovery And Development ...

The rate of cases of colitis (colon inflammation) caused by the bacteria Clostridium difficile more than doubled among patients hospitalized in the United States between 1993 and 2003, and the illness ...

An inflammation of the colon associated with C. difficile — C. difficile colitis — has increased nearly 50 percent from 2001-2005 to 2006-2010, according to a study in the Journal of the American ...

Clostridioides difficile risk is significantly higher in Korean patients with inflammatory bowel disease (IBD), which is comparable to the trend observed in Western patients with IBD. There is an ...

NEW YORK (MedscapeWire) Mar 12 — Fulminant colitis with Clostridium difficile is becoming more common and more fatal, according to a review of hospitalized patients reported in the March issue of ...

Risk for Clostridioides difficile (C. diff) infection wasn't any greater with vedolizumab (Entyvio) versus anti-tumor necrosis factor (TNF) agents for ulcerative colitis, a researcher reported. In a ...

Oct. 26 (UPI) --Research shows outpatient antibiotic use can increase a person's risk of developing C. difficile infection after discharge from the emergency room. C. difficile, is a bacterial ...

Working in the hospital again always provides valuable perspective. I love (most of) the patient care, and seeing differences in patterns over time, as I only see patients episodically. One of the ...

Clostridium difficile infection is four times more likely to kill patients with inflammatory bowel disease. C difficile is an important cause of diarrhea among inpatients, and the numbers of new cases ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ...